Previous 10 | Next 10 |
home / stock / ipsef / ipsef news
Transaction focused on Bylvay ® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen’s long-term strategy for expanding the scope of its Rare Disease p...
The CRL is related to the U.S. FDA’s previous request for additional information on palovarotene clinical trial data Ipsen anticipates responding to the request in the first quarter of 2023 Regulatory News: The U.S. Food and Drug Administration (FDA) issued a Complete Res...
The trial did not meet its primary endpoint of overall survival (OS) The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single agent The clinical trial results will be presented at a future medical meeting ...
The following slide deck was published by Ipsen S.A. in conjunction with their 2022 Q3 earnings call. For further details see: Ipsen S.A. 2022 Q3 - Results - Earnings Call Presentation
Ipsen S.A. (IPSEY) Q2 2022 Earnings Conference Call July 28, 2022 7:30 AM ET Company Participants David Loew – Chief Executive Officer Aymeric Le Chatelier – Chief Financial Officer Howard Mayer – Head of Research and Development Confer...
The following slide deck was published by Ipsen S.A. in conjunction with their 2022 Q2 earnings call. For further details see: Ipsen S.A. 2022 Q2 - Results - Earnings Call Presentation
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Epizyme (NASDAQ: EPZM ) stock is up nearly 65% today on news that the biotechnology company is going to be acquired by French pharmaceutical concern Ipsen (OTCMKTS: IPSEF ). A joint news release by the compani...
The clinical-stage oncology company Fusion Pharmaceuticals ( NASDAQ: FUSN ) announced on Thursday that the FDA cleared its Investigational New Drug (IND) applications for [225Ac]-FPI-2059 and the corresponding imaging analogue [111In]-FPI-2058. FPI-2059 is a small molecule...
The following slide deck was published by Ipsen S.A. in conjunction with their 2021 Q4 earnings call. For further details see: Ipsen S.A. 2021 Q4 - Results - Earnings Call Presentation
Ipsen S.A. (IPSEY) Q4 2021 Earnings Conference Call February 11, 2022, 8:00 AM ET Company Participants David Loew – Chief Executive Officer Aymeric Le Chatelier – Group Chief Financial Officer Howard Mayer – Head of Research and Development Conference Call Participants Je...
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...
Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...
Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration Research will focus on using Marengo’s TriSTAR platform to reinvigorate and mobilize selective V...